Latest News - Verbund AG
Top Corporates Hub
Verbund AG
A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market
02.04.2026 03:47
Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as quickly as patients, and investors, might expect. Nowhere is that more evident than in transcatheter aortic valve replacement (TAVR), a...
Jim Cramer's top 10 things to watch in the stock market Wednesday
01.04.2026 08:59
Nike's earnings were disappointing, and RH is also facing a rocky turnaround.
FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
26.03.2026 13:10
Physician using DeviceGuide with EchoNavigator 5 Physician using DeviceGuide with EchoNavigator 5 Philips DeviceGuide with EchoNavigator 5 Screen Philips DeviceGuide with EchoNavigator 5 Screen DeviceGuide with EchoNavigator 5 DeviceGuide with EchoNavigator 5 March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy pl
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
13.03.2026 14:00
New pump launches, CGM integrations and strong solvency support Tandem Diabetes' growth outlook, though intense competition and macro headwinds remain risks.
Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It?
13.03.2026 12:06
EW shares jump 22.1% in a year as growth in TMTT and strong adoption of PASCAL, EVOQUE and SAPIEN technologies fuel momentum.
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?
11.03.2026 12:38
ILMN stock surges 44.8% in a year, fueled by NovaSeq X sequencing demand, broader NGS testing adoption, multiomics expansion and improving margins.
Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript
11.03.2026 12:02
Edwards Lifesciences Corporation (EW) Leerink Global Healthcare Conference 2026 March 11, 2026 10:00 AM EDTCompany ParticipantsScott Ullem - Corporate VP...
5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
10.03.2026 13:34
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
National Vision Gains 129.5% in a Year: What's Driving the Rally?
10.03.2026 13:05
EYE stock has surged 129.5% in a year as store growth, America's Best sales, remote exam tech and transformation efforts lift comps and margins.
Should You Continue to Hold DGX Stock in Your Portfolio?
10.03.2026 12:24
Quest Diagnostics posts strong gains from physician and hospital channels while advancing AI-powered solutions.
Is Edwards Lifesciences (EW) Pricing Look Stretched After Recent Share Price Swings
08.03.2026 15:08
If you are wondering whether Edwards Lifesciences is attractively priced at its current level, this article will walk through what the numbers are really saying about the stock. The shares recently closed at US$81.64, with returns of 3.7% over the past 30 days, a 5.6% decline over the last week, and gains of 16.1% over the past year, which can change how investors think about both opportunity and risk. Over the past year, Edwards Lifesciences has stayed in focus for investors as a key player...
Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript
02.03.2026 12:07
Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose
26.02.2026 14:15
IRVINE, Calif., February 26, 2026--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access
Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
26.02.2026 13:28
How The Edwards Lifesciences (EW) Investment Story Is Shifting After Mixed Analyst Revisions
26.02.2026 11:11
Edwards Lifesciences is working with a slightly lower fair value estimate, trimmed from US$97.11 to US$96.46 per share, which puts a finer point on how analysts are thinking about the stock today. That small shift lines up with a mix of optimism and caution in recent research, where some analysts are raising price targets while others are scaling them back in light of execution and competitive risks. As you read on, you will see how these moving targets fit into the broader story and what to...
3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes
23.02.2026 13:53
ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
19.02.2026 12:05
IRVINE, Calif., February 19, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences:
Exploring the top movers within the S&P500 index during today's session.
17.02.2026 17:35
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update
15.02.2026 11:52
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales […]
Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices?
15.02.2026 09:12
AtriCure recently faced a shift in analyst sentiment when JPMorgan downgraded the company to Neutral, citing rising competitive pressure on its AtriClip device from Edwards Lifesciences’ planned surgical offering. This change highlights how competition in cardiac surgery devices can quickly alter perceptions of AtriCure’s positioning, even as other analysts maintain positive views on its prospects. We’ll now examine how JPMorgan’s concerns about Edwards Lifesciences’ competitive threat could...